Replies to post #109588 on Biotech Values

[biomaven0]

I’ll bet there have been cases where shares have been sold to unsuspecting investors based on interim (high-biased) RR data from the randomized portion of an RDT.

I personally can't think of such a case. It's not like RDTs are that common.

Here's a good free full-text article setting out the case for RDTs:

The randomized discontinuation trial: a phase II design to assess growth-inhibitory agents

1. Walter M. Stadler

http://mct.aacrjournals.org/content/6/4/1180.full